Mupirocin ointment as well as preparation and application methods thereof

Abstract

The invention provides mupirocin ointment as well as a preparation method and an application method thereof. The weight of mupirocin accounts for 0.1-0.5% of the total weight of the ointment. The water-soluble matrix is selected from polyethylene glycol, glycerol, propylene glycol or a mixture thereof. The stability and the curative effect of the medicine can be improved, and meanwhile, the safety and the use convenience of the ointment are ensured.

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical preparations, and more specifically, to a mupirocin ointment and a preparation and application method thereof. Background Art

[0002] Existing topical ointment products play an important role in the treatment of skin infections, but many products are deficient in terms of drug stability, efficacy and user experience. Traditional ointments usually contain active drug ingredients and a variety of matrix materials. Although these matrix materials, such as vaseline, lanolin and glycerin, provide the necessary moisturizing and sealing effects, they may affect the release and penetration of drugs in some cases. In addition, differences in the concentration of drug ingredients and preparation processes may lead to inconsistent therapeutic effects and even cause skin irritation or allergic reactions in some cases. During the drug preparation process, the selection and amount of solvents used also have a significant impact on the quality and safety of the final product.

[0003] In the process of implementing the embodiments of the present invention, the inventors found that there are at least the following problems or defects in the prior art: the existing method for preparing ointments may fail to fully consider the interaction between the drug ingredients and the matrix material, resulting in low drug release efficiency; the preparation process of some ointments is relatively rough, and the addition amount and mixing uniformity of the drug ingredients cannot be accurately controlled, affecting the consistency and efficacy of the product; in addition, the solvents used in the preparation process of some ointments may pose potential risks to the environment or human body, and harmful ingredients may remain in the final product. Summary of the invention

[0004] The invention provides a mupirocin ointment and a preparation method and an application method thereof.

[0005] In a first aspect, the present application provides a mupirocin ointment, comprising:

[0006] The mupirocin ointment consists of mupirocin and a water-soluble base;

[0007] The weight of mupirocin is 0.1-0.5% of the total weight of the ointment;

[0008] The water-soluble base is selected from polyethylene glycol, glycerol, propylene glycol or a mixture thereof.

[0009] As a further improvement of the present application, the weight of mupirocin is 0.3% of the total weight of the ointment.

[0010] As a further improvement of the present application, the mupirocin ointment is prepared from the following raw materials in parts by weight:

[0011] 0.1-0.5 parts of mupirocin, 15-25 parts of polyethylene glycol, 10-20 parts of glycerol, and 5-15 parts of propylene glycol.

[0012] As a further improvement of the present application, the mupirocin ointment is prepared from the following raw materials in parts by weight:

[0013] 0.3 parts of mupirocin, 20 parts of polyethylene glycol, 15 parts of glycerol, and 10 parts of propylene glycol.

[0014] As a further improvement of the present application, the mupirocin is prepared by the following method:

[0015] The mupirocin raw material is mixed with an appropriate amount of a water-soluble solvent, and the mupirocin is obtained through dissolution, filtration, concentration and drying.

[0016] As a further improvement of the present application, 1 to 5 g of mupirocin raw material is added to every 100 g of the water-soluble solvent.

[0017] In a second aspect, the present application provides a method for preparing mupirocin ointment, comprising the following steps:

[0018] (a) mixing mupirocin with an appropriate amount of a water-soluble solvent, dissolving, filtering, concentrating and drying to obtain mupirocin powder;

[0019] (b) mixing and heating the water-soluble matrix components until they are completely melted to obtain a mixed matrix;

[0020] (c) When the mixed matrix is ​​cooled to 70-80° C., mupirocin powder is added and stirred evenly to obtain the mupirocin ointment.

[0021] As a further improvement of the present application, in the step (a), the aperture of the sieve used for screening is 100 mesh.

[0022] As a further improvement of the present application, in the step (b), the temperature of the mixed matrix is ​​80 to 90° C. The above embodiments of the present invention have at least the following beneficial effects: the present invention can improve the stability and efficacy of the drug. By controlling the content of mupirocin within the range of 0.1 to 0.5% of the total weight of the ointment, particularly preferably 0.3%, the effective concentration of the drug on the skin surface can be ensured, thereby enhancing the inhibitory effect on bacteria while reducing possible side effects. In addition, through precise preparation steps, such as mixing mupirocin with an appropriate amount of solvent and then dissolving, filtering, concentrating and drying, the purity and uniform distribution of mupirocin can be ensured, further enhancing the therapeutic effect of the ointment.

[0023] At the same time, the mupirocin ointment of the present invention strictly controls the amount of solvent used during the preparation process, and 1 to 5 g of mupirocin raw material is added to every 100 g of solvent. This optimized ratio can reduce solvent residue and improve the safety of the ointment. Through meticulous process control, such as adding mupirocin powder and stirring evenly when the mixed matrix is ​​cooled to 70 to 80 ° C, the uniformity of the ointment and the effective release of the drug components can be ensured. These improvements not only improve the therapeutic effect of the ointment, but also improve the patient's experience of use, making the ointment easier to apply and absorb. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The above and other objects, features and advantages of the exemplary embodiments of the present invention will become readily understood by reading the detailed description below with reference to the accompanying drawings. In the accompanying drawings, several embodiments of the present invention are shown in an exemplary and non-limiting manner, in which:

[0025] Figure 1 The present invention provides a schematic flow chart of a method for preparing mupirocin ointment according to an embodiment of the present invention. DETAILED DESCRIPTION

[0026] The principles and spirit of the present invention will be described below with reference to several exemplary embodiments. It should be understood that these embodiments are provided only to enable those skilled in the art to better understand and implement the present invention, and are not intended to limit the scope of the present invention in any way. On the contrary, these embodiments are provided to make the present invention more thorough and complete, and to fully convey the scope of the present invention to those skilled in the art.

[0027] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. All features disclosed in this specification, or steps in all methods or processes disclosed, except for mutually exclusive characteristics and / or steps, can be combined in any way, unless otherwise described, and can be replaced by other equivalent or alternative features with similar purposes, that is, unless otherwise described, each feature is only one embodiment in a series of equivalent or similar features.

[0028] According to the modified claims, the following are the contents of the corresponding modified embodiments:

[0029] Embodiment 1:

[0030] In the present invention, mupirocin is a widely used topical antibiotic with antibacterial properties. A mupirocin ointment and its preparation and application method are prepared from the following raw materials in parts by weight: 0.3 parts of mupirocin, 20 parts of polyethylene glycol, 15 parts of glycerol, and 10 parts of propylene glycol. The weight of the mupirocin accounts for 0.1-0.5% of the total weight of the ointment. The preparation method of this embodiment includes the following steps:

[0031] S1. Mixing the mupirocin raw material with an appropriate amount of a water-soluble solvent, stirring to fully dissolve it, and then removing the insoluble matter by filtration to obtain a mupirocin solution;

[0032] S2. The polyethylene glycol, glycerol and propylene glycol are mixed and heated to 70-80° C. until completely melted to obtain a mixed matrix;

[0033] S3. Slowly add the mupirocin solution to the mixed matrix while stirring continuously to ensure uniform dispersion;

[0034] S4. During the stirring process, the temperature is maintained at 70-80° C. until the mupirocin is completely dissolved;

[0035] S5. When the mixture is cooled to 50-60°C, add preservatives and spices (if necessary) and continue stirring until uniform;

[0036] S6. Pour the mixture into an ointment tube or other container and cool to room temperature to obtain mupirocin ointment.

[0037] In this embodiment, polyethylene glycol, glycerol and propylene glycol are all cosmetic grade to ensure the safety and effectiveness of the ointment. The mupirocin ointment obtained by the above preparation method has good stability and antibacterial effect and is suitable for treating skin infections. The concentration range of mupirocin (0.1-0.5%) is determined based on its antibacterial activity and safety data to ensure the therapeutic effect of the ointment.

[0038] Embodiment 2:

[0039] In the present invention, mupirocin is a topical antibiotic used to treat skin infections. The weight of mupirocin is exactly 0.3% of the total weight of the ointment. The preparation method of the ointment comprises the following steps:

[0040] S1. accurately weighing the mupirocin raw material to ensure that it accounts for 0.3% of the total weight of the final ointment, mixing it with an appropriate amount of a water-soluble solvent, stirring it to fully dissolve it, and then removing the insoluble matter by filtration to obtain a mupirocin solution;

[0041] S2. Weigh 20 parts of polyethylene glycol, 15 parts of glycerol, and 10 parts of propylene glycol, and mix and heat to 70-80°C until completely melted to obtain a mixed matrix;

[0042] S3. Slowly add the mupirocin solution to the mixed matrix while stirring continuously to ensure uniform dispersion;

[0043] S4. During the stirring process, the temperature is maintained at 70-80° C. until the mupirocin is completely dissolved;

[0044] S5. When the mixture is cooled to 50-60°C, add preservatives and spices (if necessary) and continue stirring until uniform;

[0045] S6. Pour the mixture into an ointment tube or other container and cool to room temperature to obtain mupirocin ointment.

[0046] In this embodiment, polyethylene glycol, glycerol and propylene glycol are all cosmetic grade, and preservatives and fragrances meet the cosmetic safety standards. Through the above preparation method, the mupirocin ointment obtained has good stability and antibacterial effect, and is suitable for treating skin infections. The concentration of mupirocin is precisely controlled at 0.3%, which is determined based on its antibacterial activity and safety data to ensure the therapeutic effect of the ointment and the safety of the patient.

[0047] Embodiment 3:

[0048] In the present invention, mupirocin is a topical antibiotic used to treat skin infections. A mupirocin ointment is prepared from the following raw materials in parts by weight: 0.3 parts of mupirocin, 20 parts of polyethylene glycol, 15 parts of glycerol, and 10 parts of propylene glycol. The weight of the mupirocin is 0.1-0.5% of the total weight of the ointment. The preparation method of this embodiment includes the following steps:

[0049] S1. Mixing the mupirocin raw material with an appropriate amount of a water-soluble solvent, stirring to fully dissolve it, and then removing the insoluble matter by filtration to obtain a mupirocin solution;

[0050] S2. Mix polyethylene glycol, glycerol and propylene glycol in a weight ratio of 20:15:10 and heat to 70-80°C until completely melted to obtain a mixed matrix;

[0051] S3. Slowly add the mupirocin solution to the mixed matrix while stirring continuously to ensure uniform dispersion;

[0052] S4. During the stirring process, the temperature is maintained at 70-80° C. until the mupirocin is completely dissolved;

[0053] S5. When the mixture is cooled to 50-60°C, add preservatives and spices (if necessary) and continue stirring until uniform;

[0054] S6. Pour the mixture into an ointment tube or other container and cool to room temperature to obtain mupirocin ointment.

[0055] In this embodiment, polyethylene glycol, glycerol and propylene glycol are all cosmetic grade, and preservatives and fragrances meet the cosmetic safety standards. Through the above preparation method, the mupirocin ointment obtained has good stability and antibacterial effect, and is suitable for treating skin infections. The concentration range of mupirocin (0.1-0.5%) is determined based on its antibacterial activity and safety data to ensure the therapeutic effect of the ointment.

[0056] Embodiment 4:

[0057] In the present invention, mupirocin is a topical antibiotic used to treat skin infections. The mupirocin ointment is prepared from the following raw materials in parts by weight: 0.3 parts of mupirocin, 20 parts of polyethylene glycol, 15 parts of glycerol, and 10 parts of propylene glycol. The preparation method of this embodiment includes the following steps:

[0058] S1. Under sterile conditions, accurately weigh 0.3 parts of mupirocin, mix it with an appropriate amount of a water-soluble solvent, and stir until completely dissolved to prepare a mupirocin solution;

[0059] S2. Weigh 20 parts of polyethylene glycol, 15 parts of glycerol, and 10 parts of propylene glycol respectively, put them together in a mixing container, heat to 70-80°C, melt the materials completely and mix them evenly to form a water-soluble matrix;

[0060] S3. Under continuous stirring, slowly adding the mupirocin solution prepared in step S1 to the water-soluble matrix to ensure that the mupirocin is evenly dispersed in the matrix;

[0061] S4. Continue stirring the mixture until the mupirocin solution is completely absorbed by the water-soluble matrix to form a uniform ointment;

[0062] S5. When the mixture is cooled to 50-60°C, a trace amount of preservatives and spices (if necessary) is added to enhance the preservation and use of the ointment;

[0063] S6. Pour the mixture into a sterilized ointment container and allow it to cool and solidify naturally at room temperature to obtain mupirocin ointment.

[0064] In this embodiment, polyethylene glycol, glycerol and propylene glycol are all cosmetic grade to ensure the safety and effectiveness of the ointment. Through the above preparation method, the mupirocin ointment obtained has good stability and antibacterial effect, and is suitable for treating skin infections. The concentration of mupirocin is 0.3% of the total weight of the ointment, and this ratio is determined based on its antibacterial activity and safety data to ensure the therapeutic effect of the ointment and the safety of the patient.

[0065] Embodiment 5:

[0066] In the present invention, mupirocin is an effective topical antibiotic used to prepare an ointment with antibacterial properties. The preparation method of mupirocin is as follows:

[0067] S1. Weigh an appropriate amount of mupirocin raw material and place it in a mixing container;

[0068] S2. Add a suitable water-soluble solvent, such as polyethylene glycol 400 or water, so that the amount of solvent is sufficient to completely dissolve the mupirocin raw material, and mix the contents of the container;

[0069] S3. Under heating and stirring conditions, the mupirocin raw material is completely dissolved in the solvent to form a uniform solution;

[0070] S4. Filtering the solution through a filter medium to remove any insoluble impurities and ensure that the resulting solution is pure;

[0071] S5. Concentrating the filtered solution using a concentration device, such as a rotary evaporator, to reduce the amount of solvent and increase the concentration of mupirocin;

[0072] S6. The concentrated mupirocin solution is dried to remove the residual solvent to obtain a dry mupirocin powder;

[0073] S7. The dried mupirocin powder is crushed and sieved to obtain mupirocin fine powder that meets the particle size requirements, which is used for the preparation of the ointment.

[0074] The obtained mupirocin fine powder is mixed with matrix components such as polyethylene glycol, glycerol and propylene glycol according to the formula ratio of claim 1, and the mupirocin ointment is prepared by the following steps:

[0075] S8. The polyethylene glycol, glycerol and propylene glycol are mixed in a weight ratio according to claim 1 and heated until completely melted to form a uniform water-soluble matrix;

[0076] S9. slowly add the mupirocin fine powder into the water-soluble matrix while stirring continuously to ensure that the mupirocin is evenly dispersed in the matrix;

[0077] S10. When the mixture is cooled to 50-60°C, preservatives and flavors (if necessary) are added to enhance the storage and use of the ointment;

[0078] S11. Pour the mixture into a sterilized ointment container and allow it to cool and solidify naturally at room temperature to obtain mupirocin ointment.

[0079] In this embodiment, the quality and purity of mupirocin in the ointment are ensured by precisely controlling the preparation process of mupirocin, thereby improving the antibacterial effect of the ointment and the safety of clinical application.

[0080] Embodiment 6:

[0081] In the present invention, mupirocin is an effective topical antibiotic used to prepare an ointment with antibacterial properties. In the preparation process of mupirocin, 1 to 5 grams of mupirocin raw material is added to every 100 grams of water-soluble solvent. The preparation method of this embodiment includes the following steps:

[0082] S1. Accurately weigh an appropriate amount of mupirocin raw material, ranging from 1 to 5 grams, according to the desired mupirocin concentration;

[0083] S2. The weighed mupirocin raw material is added to 100 g of a pre-measured aqueous solvent, the solvent may be polyethylene glycol 400, propylene glycol or other suitable solvent;

[0084] S3. Under heating and stirring conditions, the mupirocin raw material is completely dissolved in the solvent to form a uniform solution. If necessary, ultrasonic dissolution can be used to assist dissolution to improve dissolution efficiency;

[0085] S4. Filter the solution using a filtration device to remove any undissolved particles or impurities to ensure the clarity of the solution;

[0086] S5. Concentrate the filtered solution to reduce the amount of solvent and increase the concentration of mupirocin. This step can be achieved by a rotary evaporator or a vacuum concentration device;

[0087] S6. The concentrated solution is dried to remove the residual solvent to obtain a dry mupirocin powder;

[0088] S7. The dried mupirocin powder is crushed and sieved to obtain mupirocin fine powder that meets the particle size requirements, which is used for the preparation of the ointment.

[0089] The obtained mupirocin fine powder was mixed with matrix components such as polyethylene glycol, glycerol and propylene glycol according to the formula ratio of Example 1, and mupirocin ointment was prepared by the following steps:

[0090] S8. The polyethylene glycol, glycerol and propylene glycol are mixed in a weight ratio according to claim 1 and heated until completely melted to form a uniform water-soluble matrix;

[0091] S9. slowly add the mupirocin fine powder into the water-soluble matrix while stirring continuously to ensure that the mupirocin is evenly dispersed in the matrix;

[0092] S10. When the mixture is cooled to 50-60°C, preservatives and flavors (if necessary) are added to enhance the storage and use of the ointment;

[0093] S11. Pour the mixture into a sterilized ointment container and allow it to cool and solidify naturally at room temperature to obtain mupirocin ointment.

[0094] In this embodiment, the quality and purity of mupirocin in the ointment are ensured by precisely controlling the addition amount of the mupirocin raw material and the amount of the solvent, thereby improving the antibacterial effect of the ointment and the safety of clinical application.

[0095] Embodiment 7:

[0096] In the present invention, mupirocin is an effective topical antibiotic used to prepare an ointment with antibacterial properties. The preparation method of mupirocin ointment comprises the following steps:

[0097] (a) mixing mupirocin with an appropriate amount of a water-soluble solvent, dissolving, filtering, concentrating and drying to obtain mupirocin powder;

[0098] (b) mixing polyethylene glycol, glycerol and propylene glycol and heating them until they are completely melted to obtain a mixed matrix;

[0099] (c) When the mixed matrix is ​​cooled to 70-80° C., mupirocin powder is added and stirred evenly to obtain the mupirocin ointment.

[0100] In step (a), the sieve used for sieving has an aperture of 100 meshes to ensure that the particle size of the mupirocin powder is uniform and fine, which is conducive to subsequent mixing with the matrix.

[0101] In step (b), the temperature of the mixed matrix is ​​controlled at 80-90° C. This temperature range is conducive to the complete melting and mixing of the matrix components, while ensuring that the stability and biological activity of the mupirocin powder can be effectively maintained when it is added in the next step.

[0102] The specific preparation steps are as follows:

[0103] S1. Accurately weigh the mupirocin raw material, mix it with an appropriate amount of a water-soluble solvent (such as polyethylene glycol 400 or water), heat and stir until it is completely dissolved to form a uniform solution;

[0104] S2. The solution was filtered through a 100-mesh sieve to remove insoluble impurities to obtain a pure mupirocin solution;

[0105] S3. The filtered mupirocin solution is concentrated to remove the solvent to obtain a concentrated solution;

[0106] S4. The concentrated solution is dried to obtain mupirocin powder;

[0107] S5. Weigh appropriate amounts of polyethylene glycol, glycerol and propylene glycol, mix them and heat them to 80 to 90° C. until they are completely melted to form a uniform mixed matrix;

[0108] S6. When the mixed matrix is ​​cooled to 70-80° C., the mupirocin powder obtained in step S4 is slowly added to the mixed matrix while stirring continuously to ensure that the mupirocin powder is evenly dispersed in the matrix;

[0109] S7. Continue stirring the mixture until the ointment reaches the desired uniformity and consistency;

[0110] S8. Fill the prepared mupirocin ointment into a sterilized ointment container, cool it to room temperature, and then seal it for storage.

[0111] The mupirocin ointment obtained by the above preparation method has good stability and antibacterial effect and is suitable for treating skin infections. The precise control of each step ensures the quality and efficacy of the ointment, making it a safe and effective treatment option.

[0112] Example 8

[0113] like Figure 1 As shown, in some embodiments, the preparation method 100 of mupirocin ointment includes the following steps:

[0114] a. mixing mupirocin with an appropriate amount of a water-soluble solvent, dissolving, filtering, concentrating and drying to obtain mupirocin powder;

[0115] First, mix the mupirocin raw material with a water-soluble solvent. For example, take 3 grams of mupirocin and mix it with 100 milliliters of distilled water at room temperature and keep it under stirring for 1 hour to ensure that the mupirocin is completely dissolved. Subsequently, the solution is filtered through a 0.22 micron microporous filter membrane to remove insoluble impurities and obtain a clear mupirocin solution. Next, the solution is concentrated at 40°C using a rotary evaporator to reduce the amount of solvent and increase the concentration of mupirocin. Finally, the concentrated solution is spray dried at 50°C to remove the residual solvent to obtain a dry mupirocin powder.

[0116] b. mixing and heating the water-soluble matrix components until completely melted to obtain a mixed matrix;

[0117] Weigh appropriate amounts of water-soluble matrix components, such as polyethylene glycol 400, glycerol and propylene glycol, and mix them in a predetermined ratio. For example, take 50 parts of polyethylene glycol 400, 30 parts of glycerol and 20 parts of propylene glycol, heat these raw materials to 70-80°C in a mixing container, and continue stirring until all components are completely melted to form a uniform transparent matrix. In this process, the heating temperature and time can be appropriately adjusted according to actual conditions to ensure the uniformity and stability of the matrix.

[0118] c. When the mixed matrix is ​​cooled to 70-80° C., mupirocin powder is added and stirred evenly to obtain the mupirocin ointment.

[0119] When the water-soluble matrix is ​​cooled to 70-80°C, the mupirocin powder obtained in step a is slowly added to the matrix, and stirring is maintained to ensure that the mupirocin powder is evenly dispersed. During the stirring process, the temperature is maintained at 70-80°C until the mupirocin powder is completely dissolved. Subsequently, the mixture is cooled to room temperature, and stirring is continued during this period to ensure the uniformity and stability of the ointment. The mupirocin ointment finally obtained has good stability and antibacterial effect, and is suitable for treating skin infections.

[0120] Comparative Example 1:

[0121] This comparative example is a mupirocin ointment, which is prepared from the following raw materials in parts by weight:

[0122] 0.2 parts of mupirocin, 20 parts of polyethylene glycol, 10 parts of glycerol and 10 parts of propylene glycol;

[0123] The preparation method of the mupirocin ointment comprises the following steps:

[0124] (a) mixing mupirocin with an appropriate amount of water, stirring to fully dissolve the mupirocin, and then filtering to remove insoluble matter to obtain a mupirocin solution for use;

[0125] (b) mixing polyethylene glycol, glycerol and propylene glycol and heating them to 80° C., and after they are completely melted, obtaining a mixed matrix;

[0126] (c) When the mixed matrix is ​​cooled to 60° C., the mupirocin solution is added and stirred to obtain the mupirocin ointment.

[0127] Comparative Example 2:

[0128] This comparative example is a mupirocin ointment, which is prepared from the following raw materials in parts by weight:

[0129] 0.4 parts of mupirocin, 25 parts of polyethylene glycol, 15 parts of glycerol and 10 parts of propylene glycol;

[0130] The preparation method of the mupirocin ointment comprises the following steps:

[0131] (a) mixing mupirocin with an appropriate amount of water, stirring to fully dissolve the mupirocin, and then filtering to remove insoluble matter to obtain a mupirocin solution for use;

[0132] (b) mixing polyethylene glycol, glycerol and propylene glycol and heating them to 85° C., and after they are completely melted, obtaining a mixed matrix;

[0133] (c) When the mixed matrix is ​​cooled to 70° C., the mupirocin solution is added and stirred to obtain the mupirocin ointment.

[0134] Experimental example:

[0135] The mupirocin ointment prepared in Example 1 and Comparative Examples 1-2 was obtained respectively;

[0136] The above mupirocin ointment was used to treat patients with skin infections, with symptoms such as redness, swelling, itching, exudation, etc.; among them, the ointment of Example 1 treated a total of 63 patients, the ointment of Comparative Example 1 treated a total of 41 patients, and the ointment of Comparative Example 2 treated a total of 36 patients;

[0137] Treatment:

[0138] Use a cotton swab to apply the ointment to the affected area 3 times a day. Continue applying for 7 days, and then follow up on the efficacy.

[0139] Criteria for judging efficacy:

[0140] Cure: All clinical symptoms disappear without recurrence;

[0141] Markedly effective: more than two-thirds of clinical symptoms disappeared;

[0142] Effective: clinical symptoms are alleviated;

[0143] Ineffective: Clinical symptoms remained unchanged or aggravated.

[0144] The statistical efficacy is shown in Tables 1 to 3:

[0145] Group cure Significant effect efficient invalid Example 1 42 17 4 0 Comparative Example 1 21 14 5 1 Comparative Example 2 19 9 8 0

[0146] Table 2 Statistics of therapeutic effects on eczema lesions

[0147] Group cure Significant effect efficient invalid Example 1 35 22 6 0 Comparative Example 1 15 12 9 5 Comparative Example 2 12 10 11 3

[0148] Table 3 Statistics of efficacy of acne lesions

[0149] Group cure Significant effect efficient invalid Example 1 45 18 3 0 Comparative Example 1 20 15 6 0 Comparative Example 2 18 14 4 0

[0150] From Tables 1 to 3, we can see that:

[0151] The mupirocin ointment prepared by the technical scheme of the present application and the comparative example has a certain therapeutic effect on different types of skin lesions. Compared with the comparative example, the mupirocin ointment prepared by the technical scheme of the present application has a significant therapeutic effect on skin lesions such as eczema and acne.

[0152] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. These modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be included in the scope of the claims and specification of the present invention.

[0153] The above descriptions are only some preferred embodiments of the present invention and an explanation of the technical principles used. Those skilled in the art should understand that the scope of the invention involved in the embodiments of the present invention is not limited to the technical solutions formed by a specific combination of the above technical features, but should also cover other technical solutions formed by any combination of the above technical features or their equivalent features without departing from the above inventive concept. For example, the above features are replaced with (but not limited to) technical features with similar functions disclosed in the embodiments of the present invention to form a technical solution.

Claims

1. A mupirocin ointment, characterized in that: The mupirocin ointment consists of mupirocin and a water-soluble base; The weight of mupirocin is 0.1-0.5% of the total weight of the ointment; The water-soluble base is selected from polyethylene glycol, glycerol, propylene glycol or a mixture thereof.

2. The mupirocin ointment according to claim 1, characterized in that The weight of mupirocin is 0.3% of the total weight of the ointment.

3. The mupirocin ointment according to claim 1, characterized in that The mupirocin ointment is prepared from the following raw materials in parts by weight: 0.1-0.5 parts of mupirocin, 15-25 parts of polyethylene glycol, 10-20 parts of glycerol, and 5-15 parts of propylene glycol.

4. The mupirocin ointment according to claim 1, characterized in that The mupirocin ointment is prepared from the following raw materials in parts by weight: 0.3 parts of mupirocin, 20 parts of polyethylene glycol, 15 parts of glycerol, and 10 parts of propylene glycol.

5. The mupirocin ointment according to claim 1, characterized in that The mupirocin is prepared by the following method: The mupirocin raw material is mixed with an appropriate amount of a water-soluble solvent, and the mupirocin is obtained through dissolution, filtration, concentration and drying.

6. The mupirocin ointment according to claim 5, characterized in that 1 to 5 g of mupirocin raw material is added to every 100 g of the water-soluble solvent.

7. The method for preparing the mupirocin ointment according to any one of claims 1 to 6, characterized in that: The steps include: (a) mixing mupirocin with an appropriate amount of a water-soluble solvent, dissolving, filtering, concentrating and drying to obtain mupirocin powder; (b) mixing and heating the water-soluble matrix components until they are completely melted to obtain a mixed matrix; (c) When the mixed matrix is ​​cooled to 70-80° C., mupirocin powder is added and stirred evenly to obtain the mupirocin ointment.

8. The preparation method according to claim 6, characterized in that: In the step (a), the sieve used for sieving has an aperture of 100 meshes.

9. The preparation method according to claim 6, characterized in that: In the step (b), the temperature of the mixed matrix is ​​80-90°C.

Images